By Diagram Insights
Published: 2026-11-18 | 10 min read | Region: Asia-Pacific region
Topics: Alzheimer’s disease, dementia, neurology
Across the Asia-Pacific region, the science of Alzheimer’s disease is advancing faster than the systems designed to deliver it — and the decisions made in the next few years will determine who benefits.
Every September, World Alzheimer’s Month brings a wave of awareness campaigns, statistics, and calls to action. The numbers are striking. The testimonies are moving. The political declarations are often sincere. And yet, across the Asia-Pacific region, the systems to translate that awareness into earlier diagnosis, equitable treatment access, and meaningful patient outcomes still don’t yet exist.
This September, the gap between what we know and what we have built to act on it has never been more visible — or more consequential. Parts 1 and 2 of this series established the scale of the challenge and the tools now available to address it.
An estimated 130 million people across the nine economies studied for this analysis are living with preclinical Alzheimer’s disease — developing the condition without symptoms and invisible to health systems which aren’t designed to find them.¹ Blood-based biomarker (BBBM) testing now offers a scalable, cost-effective route to identify those patients earlier, at the primary care level, before the window for effective intervention has closed.² ³
The question that remains is the hardest one: given the tools, the evidence, and the scale of what is at stake — what does it actually take to build a health system ready to act?
The answer requires movement on four fronts simultaneously: equity, data infrastructure, funding reform, and patient advocacy. None of them alone will succeed. All are necessary together.
Equity: the next battleground
As emerging anti-amyloid therapies move closer to widespread clinical use across the region, the risk is a familiar one in global health: innovation arrives, but unequally.
These treatments require biomarker-confirmed diagnosis as a prerequisite for eligibility. They require specialist-level interpretation, MRI monitoring infrastructure, and follow-up capacity. They are, by design, complex interventions.
In health systems where specialist capacity is concentrated in urban tertiary centres and biomarker testing is only available out-of-pocket, the architecture of these therapies risks reproducing the inequalities that already define too much of the region’s approach to Alzheimer’s disease. Rural populations in many economies already travel hours for any specialist appointment. For many communities, a treatment pathway that begins with biomarker confirmation at a tertiary centre is an insurmountable barrier.
A scorecard assessment across nine Asia-Pacific economies shows the progress still to make, even in the region’s strongest performers4. Australia, Hong Kong, Japan, Singapore, South Korea, and Taiwan score moderately high on treatment access; they have regulatory approvals for disease-modifying therapies and established care frameworks. Japan leads the region, with lecanemab and donanemab both fully reimbursed under national health insurance from late 2023 and 2024 respectively, alongside dedicated biomarker guidelines4.
But even across this group, biomarker reimbursement pathways are still absent or partial, and no economy has established funded BBBM triage at the primary care level.⁴ In advocacy and education, Australia, Japan, Singapore, and South Korea score highly — but Hong Kong and Thailand show limited formal patient organisation participation in national policy planning, and Thailand’s overall policy and planning score is the lowest in the group.
The tools to close these gaps are available. Hub-and-spoke diagnostic networks can extend testing to secondary hospitals and community facilities, connecting rural and underserved populations to specialist capacity through remote consultations and structured referrals.⁵ Task-shifting protocols can also enable primary care physicians and community health workers to conduct BBBM triage, reserving specialist time for confirmatory assessment and treatment planning rather than initial screening.⁵
Two of the region’s community models show what equitable delivery can look like in practice. Taiwan’s Dementia Integrated Care Centers — multidisciplinary teams combining medical, care, and support functions across 114 facilities — prove that integrated care doesn’t require tertiary hospitals.⁶ Japan’s Team Orange programme offers a complementary model that has become a regional benchmark for community-level dementia support. Launched under the national dementia policy framework, Team Orange builds nationwide networks of trained volunteers — including people living with dementia — who provide wellness promotion, social engagement, and referral support at the municipal level. The programme explicitly aims to connect people to the formal health system earlier and more consistently, functioning as a community infrastructure layer that sits upstream of clinical services.⁷
payers, clinicians, and policymakers alike.⁸For mature health systems — Australia, Japan, South Korea, Singapore, Taiwan, Hong Kong, and New Zealand — equity means ensuring that the diagnostic and treatment infrastructure being built reaches beyond tertiary centres to primary care and rural communities. For emerging systems — China and Thailand — it means building that infrastructure in ways that are scalable from the outset, rather than replicating the urban concentration that has made access so uneven elsewhere.⁵
Data: we cannot manage what we do not measure
Across almost every economy in the Asia-Pacific region, the data infrastructure needed to plan, monitor, and improve Alzheimer’s disease care simply does not exist at scale. Registries dedicated specifically to Alzheimer’s disease are still rare. Existing data systems tend to be hospital-based, incomplete, or project-driven. The interoperability between registries, electronic health records, payer systems, and clinical datasets that would allow for systematic analysis of diagnostic timelines, biomarker uptake, treatment eligibility, and outcomes is largely absent.⁸
Without reliable national data, health technology assessments aren’t made on robust evidence. Forecasting of long-term care demand is speculative. Capacity planning for treatment pathways is based on assumptions. And the equity dimensions of the challenge — the rural-urban diagnostic gap, the disparity in biomarker access across income levels, the variation in treatment eligibility across health system tiers — are invisible to the policymakers who need to address them.⁸
Japan and South Korea are the exceptions that demonstrate what’s possible. Japan maintains a DMT Registry, enrolling Alzheimer’s disease patients treated with anti-amyloid therapies and capturing real-world safety and efficacy data4. South Korea operates two complementary systems: K-DReaMS, a national registry covering nearly 45% of adults aged 65 and above, which tracks dementia prevalence, service use, and outcomes at population scale; and JOYALZ, a multi-centre registry launched by the Korean Dementia Association specifically to capture real-world data on new Alzheimer’s disease drugs and diagnostics approved since 2021.⁹ Together, these systems show what Alzheimer’s-specific data infrastructure looks like when registry development is treated as a policy priority rather than a research project.
The path forward is structured and achievable. Health systems across the region should develop or expand dedicated Alzheimer’s disease registries capturing CSF and BBBM testing, disease-modifying therapy eligibility, treatment uptake, and patient outcomes — linked to payer datasets to support health economic analyses. National data definitions should be standardised. Digital data-exchange frameworks should be established, with annual reporting obligations that make diagnostic access, biomarker adoption, and treatment equity visible to payers, clinicians, and policymakers alike.⁸
Funding: the redirection strategy
Across the region, most health budgets are structured around late-stage disease management: institutional long-term care, acute hospital episodes, and crisis-driven interventions that arrive after the most significant damage has been done. This is the most expensive way to manage a progressive disease, and the evidence shows it locks health systems into a permanent cycle of escalating costs.
What’s needed is a Dementia Care Redirection Policy — a formal mechanism, mandated by Ministries of Finance, to systematically quantify the escalating fiscal burden of late-stage, institutional long-term care and reallocate a defined portion of that expenditure toward upstream interventions: early Alzheimer’s disease screening, biomarker-confirmed diagnosis, and system readiness for disease-modifying therapies.⁵
This is a structural reorientation of how Alzheimer’s disease is financed, away from reactive management of advanced disease and toward the earlier stages where intervention is both clinically and economically most effective. Reallocating even a modest share of late-stage care spending can unlock the resources needed to build early detection infrastructure. UK modelling shows the returns available: a nationwide rollout of early diagnosis memory services, preventing just 10% of care home admissions, would deliver annual public expenditure savings that approach the cost of the programme itself within a decade.¹⁰ Every USD 1 invested in early diagnosis and system preparedness is estimated to save USD 5 in future institutional care spending over the longer term.¹¹
Alongside this structural reorientation, bundled payment models can provide the reimbursement architecture for the disease-modifying therapy era. In a bundled model, any newly approved disease-modifying therapy would be financed as an integrated package — with biomarker confirmation funded, safety monitoring funded, and eligibility criteria clearly defined. This eliminates the siloed cost problem that currently prevents diagnostic infrastructure from being developed in step with therapeutic access.¹²
Health technology assessment fast-tracks for both disease-modifying therapies and companion diagnostics are equally essential. Reimbursement frameworks that lag years behind scientific progress actively delay patient access and widen the equity gap between those who can afford private access and those who cannot.¹²
Patient advocacy: shifting the ask
The final element cannot be delivered by governments, health systems, or the clinical community alone. It depends on patient advocacy networks across the region — and on whether that network makes a strategic shift in what it asks for.
Across the Asia-Pacific region, patient and caregiver organisations have historically focused their advocacy on care: support services, caregiver training, community awareness, stigma reduction. The value of these contributions should not be diminished. But the advocacy agenda needs to expand to include access — specifically, access to BBBM diagnosis and to the therapies that require it.
This shift matters in particular because the scorecard assessment reveals uneven engagement: while Australia, Japan, New Zealand, and South Korea have patient organisations formally embedded in national dementia policy development, organisations in Hong Kong and Thailand show limited participation in planning processes. Formalising this engagement — through mandated roles in national Alzheimer’s disease planning committees — is itself a policy recommendation that governments should adopt.⁴
Patient organisations should be officially designated as patient navigation hubs within national dementia strategies, receiving government funding and mandates to guide patients through diagnostic and referral pathways, and to address the access and equity barriers that prevent rural and underserved communities from reaching the services that exist.⁴
Asking for better care is important. But asking for earlier diagnosis, for biomarker reimbursement, for funded DMT pathways, for equity monitoring and public reporting, is what determines whether the science of Alzheimer’s disease translates into population-level change — or remains available only to those already positioned to access it.
What comes next: the high-impact agenda
BBBMs are validated and scalable. Disease-modifying therapies are approved and entering clinical use across several Asia-Pacific markets. The evidence base for early intervention — clinical, economic, and humanitarian — is as strong as it has ever been.
What’s not yet ready, in most economies across the region, is the system. And system readiness depends on governments acting now on a specific set of high-impact priorities.
First: mandate standalone, costed national Alzheimer’s disease action plans. Not embedded within broader dementia or ageing frameworks, but ring-fenced, with disease-specific targets, dedicated budgets, and accountability mechanisms. No economy in the region currently earmarks a dedicated budget specifically for Alzheimer’s disease programmes. That must change.⁵
Second: build national Alzheimer’s disease registries. Every economy should develop or expand data infrastructure capturing biomarker testing, DMT eligibility, treatment uptake, and patient outcomes — linked to payer datasets, standardised nationally, and published annually. The K-DReaMS and JOYALZ models in South Korea, and Japan’s DMT Registry, provide the blueprint.⁹
Third: task-shift to primary care. BBBM triage should be a primary care function, not a specialist one. Training primary care physicians and community health workers to conduct BBBM triage — with structured referral pathways to confirmatory testing — is the mechanism by which diagnostic access becomes equitable rather than concentrated in high-resource settings.⁵
Fourth: launch public awareness campaigns on early detection. World Alzheimer’s Month is the natural platform — but awareness that Alzheimer’s disease begins decades before symptoms, and that it can now be detected through a blood test, must become a year-round public health message. Until populations understand that preclinical disease is detectable and actionable, demand for early testing will not be sufficient to drive system change.¹
The decisions made in the next few years will determine whether the Asia-Pacific region builds a system capable of delivering on the promise of the new science. Or whether the 71 million people in the Asia-Pacific region forecasted to develop Alzheimer’s disease by 2050 continue through the disease continuum without support, until health systems are overwhelmed — and the human, financial, and societal cost falls on families who were never equipped to bear it.¹³